Mayo researchers explore reasons for complications with kidney failure patientsAugust 18, 2005ROCHESTER, Minn. - Mayo Clinic researchers searching for explanations of high mortality rates among kidney failure patients undergoing hemodialysis are focusing their attention on the use of heparin, a drug used to reduce clotting of the blood. Their study in the August issue of Mayo Clinic Proceedings is a preliminary look at one aspect affecting the health of patients who undergo hemodialysis. In the study, they found patients who had a higher level of adverse outcomes also had elevated levels of heparin antibodies in their blood. The authors believe this is the first study examining this association. However, Robert McBane, M.D., a Mayo Clinic cardiovascular disease specialist who led the study, cautions that these results are preliminary. "These results are thought-provoking and hypothesis-generating, but at this point we need more study," says Dr. McBane. "Patients requiring hemodialysis have a high mortality rate for reasons which are not clear. The search for variables contributing to this mortality rate is of prime importance." Heparin is an anticoagulant, which is usually used to prevent the formation of blood clots in the blood vessels that can prove harmful. For patients with end-stage renal disease (kidney failure), hemodialysis is the most common form of therapy. Recent figures show more than 85 percent of the approximately 379,000 patients with the disease were treated this way. In hemodialysis, the patient's blood is passed through a machine to clean it, similar to what the kidneys might do if the body was functioning normally. Heparin must be used to prevent clotting of the blood in the dialysis machine in order to safely perform hemodialysis. At this time, there are no other widely-used alternatives to heparin. The results of this analysis, if confirmed by others, might stimulate the search for better anticoagulants that can be used in hemodialysis. The study found that the presence of heparin antibodies in hemodialysis patients was associated with more adverse outcomes compared with hemodialysis patients without detectable antibodies. If the findings are confirmed by others, physicians might test for the presence of these antibodies to determine if a patient might be at an above-average risk for complications. Co-authors in the study include Lourdes Pena de la Vega, M.D., Randal Miller, Margaret Benda, Diane Grill, Matthew Johnson, and James McCarthy, M.D. In an editorial in the same issue of Mayo Clinic Proceedings, Donald Arnold, M.D., and John Kelton, M.D., of the Department of Medicine, Michael G. DeGroote School of Medicine at McMaster University in Hamilton, Ontario, Canada, say the study adds to the evidence that the heparin antibodies may be an indicator of problems even if other symptoms aren't evident. But they also say further study is needed. Mayo Clinic |
|||||||||||||||||||||
| Related Kidney Failure Current Events and Kidney Failure News Articles Key player identified in cascade that leads to hypertension-related kidney damage A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Kidney transplants generally safe for lupus patients Individuals with a history of lupus who receive a kidney transplant rarely develop the serious inflammatory condition lupus nephritis in their new organ, according to a paper being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA. A decade later, lifestyle changes or metformin still lower type 2 diabetes risk Intensive lifestyle changes aimed at modest weight loss reduced the rate of developing type 2 diabetes by 34 percent compared with placebo in people at high risk for the disease, researchers conclude based on 10 years of data. Calculate benefit before dialysis for frail elders Kidney specialists should weigh the potential quality of life for frail elders with end-stage renal disease (ESRD) in opting for dialysis over more conservative therapies, a nephrologist and a palliative care specialist suggest in an editorial in the New England Journal of Medicine. Study questions need for routine intervention in patients with renovascular disease Some invasive procedures that are becoming increasingly common as a first line of treatment for patients diagnosed with narrowed arteries in and around the kidneys may not be necessary. Ironing out the genetic cause of hemoglobin problems A gene with a significant effect on regulating hemoglobin in the body has been identified as part of a genome-wide association study, which looked at the link between genes and hemoglobin level in 16,000 people. National report shines light on lupus 50-year treatment drought Today, The Lewin Group, a national health care consulting firm, issued recommendations on ways to overcome the barriers that have obstructed lupus drug development resulting in no new drug approval for this disease in more than 50 years - since the Eisenhower Administration. Kidneys from deceased donors with acute renal failure expand donor pool Kidneys recovered from deceased donors with acute renal failure (ARF) - once deemed unusable for transplant - appear to work just as well as kidneys transplanted from deceased donors who do not develop kidney problems prior to organ donation. Study details safe, effective, minimally invasive mitral valve repair Surgical treatment for mitral valve disease includes either repairing the patient's diseased valve or replacing it with a metal, mechanical valve or an animal tissue valve. Rare genetic disease successfully reversed using stem cell transplantation A recent study by Scripps Research Institute scientists offers good news for families of children afflicted with the rare genetic disorder, cystinosis. More Kidney Failure Current Events and Kidney Failure News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||